Iterum Therapeutics Q1 net loss $9.9M; cash $51.8M; REASSURE trial on track

Iterum Therapeutics plc

2023-Q1 EPS reported -$0.78

Net loss Q1 2023 $9.9M vs $3.5M Q1 2022; non-GAAP net loss $7.4M vs $5.6M.
Cash and investments $51.8M as of March 31, 2023; expected to fund operations until mid-2024.
R&D expense $6.4M (up from $3.4M) due to REASSURE; G&A $2.1M (down from $3.9M).
REASSURE trial enrollment ongoing; completion expected H1 2024; interim analysis H2 2023.
Approximately 12.9M ordinary shares outstanding as of April 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.

Period: first quarter ended March 31, 2023
Net income: Net loss for the first quarter 2023 was $9.9 million
Result: reported results

Exact text from the filing

Iterum Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Iterum Therapeutics plc reported first quarter ended March 31, 2023 results: net income Net loss for the first quarter 2023 was $9.9 million.

Period: first quarter ended March 31, 2023
Net income: Net loss for the first quarter 2023 was $9.9 million
Result: reported results

Exact text from the filing

Net loss for the first quarter 2023 was $9.9 million, compared to a net loss of $3.5 million for the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-23-021495

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.